Millipore to collaborate with Roka Bioscience to develop molecular tests

Millipore, a provider of technologies, tools and services for the global life science industry, has reported that it will collaborate with Roka Bioscience to develop molecular assays and portable instruments for biopharmaceutical production. Roka Bioscience is a new, independent company created through the spin-off of Gen-Probe's industrial assets.

Millipore and Gen-Probe formed an exclusive partnership in 2005 to develop faster, more reliable and sensitive tests for contaminants commonly found in pharmaceutical and biotechnology manufacturing processes.

In 2008, they introduced the MilliPROBE system, which is the first solution of its kind and combines Millipore's sample prep methodologies with Gen-Probe's advanced, nucleic acid technologies to deliver both speed and sensitivity in one microbial screening tool. The companies currently have one assay on the market for Pseudomonas aeruginosa and are developing a second assay for Mycoplasma that remains on track to be introduced early in 2010.

Jean-Paul Mangeolle, president of bioprocess division at Millipore, said: "We believe that the creation of Roka Bioscience will help us to accelerate the development of further MilliPROBE assays due to the focus and investment they will bring to the partnership.

"Roka Bioscience's investment into a fully integrated, portable testing instrument will also bring us closer to our vision of providing rapid tests that can be conducted right on the manufacturing floor. We remain very excited about the market potential for the MilliPROBE platform and about the major milestone that the launch of our Mycoplasma assay will represent for our partnership."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: biotechnology, industrial, investment, manufacturing, partnership, pharmaceuticals, president, technology, track